|
|
|
|
|
Adalimumab
drug data and news
Adalimumab drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Adalimumab | ||
| Brand Names/Synonyms | Ig gamma-1 chain C region; Humira (Abbott Laboratories) | ||
| Indication | For treatment of rheumatoid arthritis | ||
| Sponsored links | Description | Anti-TNF antibody, expressed in mammalian cell culture, 1330 residues, MW=148 kD. Humira was created using phage display technology resulting in an antibody with human derived heavy and light chain variable regions and human IgGl:K constant regions. It is produced by recombinant DNA technology in a mammalian cell expression system | |
| Pharmacology | Used in the treatment of rheumatoid arthritis. Elevated levels of TNF are found in the synovial fluid of rheumatoid arthritis patients and play an important role in both the pathologic inflammation and the joint destruction that are hallmarks of the disease. Adalimumab binds specifically to TNF-alpha and blocks its general cytokine effects, thereby reducing TNF-induced inflammation and halting the joint destruction. | ||
| Mechanism Of Action | Adalimumab binds to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also lyses surface TNF expressing cells in vitro in the presence of complement. | ||
| Adalimumab News (When available) |
FDA clears Rituxan for rheumatoid arthritis Mar 1, 2006 Genentech, Biogen Idec Gain Approval Of Rituxan In RA Mar 1, 2006 New US Patent 6,982,089 Issued - Describing a Novel Biotechnology ... Feb 20, 2006 Rheumatic Diseases Remain a Significant Cause of Chronic Illness ... Feb 22, 2006 Cambridge Antibody Technology Group plc Announces First Quarter ... Feb 5, 2006 Better Fix For Rheumatoid Arthritis Feb 16, 2006 Cambridge Antibody Technology Group plc Announces First Quarter ... Feb 5, 2006 Inflammatory Diseases - Both Chronic Diseases, Such as Rheumatoid ... Feb 1, 2006 | ||
| Dosage Forms | Solution | ||
| Drug_Category | Immunomodulatory Agents; Antirheumatic Agents; unclassified therapeutic agents (92:00.00) | ||
| Absorption | Not Available | ||
| Interactions | Not Available | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | Humanized anti-TNF antibody (D2E7) | ||
| Chemical Formula | C6428H9912N1694O1987S46 >Mouse-Human chimeric chain 1 Anti-TNF alpha VL >Mouse-Human chimeric chain 2 Anti-TNF alpha VH >Mouse-Human chimeric chain 2 Anti-TNF alpha VL | ||
| Molecular Weight | 144190.3 | ||
| Smiles String | Not Available | ||
| Melting Point | Not Available | ||
| Water Solubility | Not Available | ||
| State | Transparent, slightly viscous, aqueous liquid | ||
| LogP/Hphobicity | -0.441 | ||
| Isoelectric Point | 8.25 | ||
| Biotransformation | Most likely removed by opsonization via the reticuloendothelial system. | ||
| Half Life | 10-20 days. | ||
| Protein Binding [%] | Not Available | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Adalimumab.html http://www.rxlist.com/cgi/generic3/humira.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | BIOD00049 | ||
| CAS Registry Number | 331731-18-1 | ||
| KEGG Compound ID | Not Available | ||
| PubChem ID | Not Available | ||
| PharmGKB ID | PA10004 | ||
| SwissProt ID | IGHG1_HUMAN (P01857) | ||
| GenBank ID | J00228 | ||
| Drug ID Number [DIN] | 2258595 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |